Advances in imaging of the solitary pulmonary nodule by Yau, YY et al.
Title Advances in imaging of the solitary pulmonary nodule
Author(s) Ooi, GC; Khong, PL; Yau, YY
Citation Hong Kong Medical Journal, 2004, v. 10 n. 2, p. 107-116
Issued Date 2004
URL http://hdl.handle.net/10722/44683
Rights Creative Commons: Attribution 3.0 Hong Kong License
Hong Kong Med J Vol 10 No 2 April 2004     107
REVIEW ARTICLE
Key words:
Diagnostic imaging;
Lung neoplasms;
Technology, radiologic;
Tomography, X-ray computed
 !
 !"#
 !
 !"#$
 !"#
Hong Kong Med J 2004;10:107-16
Advances in imaging of the solitary
pulmonary nodule
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
 !"#$%&'(
Department of Diagnostic Radiology,
The University of Hong Kong,
Queen Mary Hospital, Pokfulam,
Hong Kong
GC Ooi, MRCP, FRCR
PL Khong, FRCR, FHKCR
Diagnostic Imaging Services, Hong Kong
Adventist Hospital, Hong Kong
YY Yau, FRANZCR, FHKCR
Correspondence to: Dr GC Ooi
(e-mail: cgcooi@hkucc.hku.hk)
GC Ooi  
PL Khong  
YY Yau  
Objective. To review the radiological management of a solitary pulmonary nodule.
Data sources. MEDLINE literature search (1958-2002).
Study selection. All review articles and original articles. Key words for the lit-
erature search were ‘solitary pulmonary nodule’ and ‘imaging’.
Data extraction. All relevant information and data.
Data synthesis. The solitary pulmonary nodule remains a perennial problem in
radiological practice, particularly with current trends using low-dose computed
tomography to screen for lung cancer. Determining the likelihood of malignancy
forms the basis of the radiological approach of a solitary pulmonary nodule.
Several factors that influence risk analysis include morphological and enhance-
ment characteristics of the solitary pulmonary nodule on imaging, stability of
the nodule, age of patient, smoking history, and history of malignant disease.
Other ancillary procedures and imaging techniques that assist in the evaluation
of a solitary pulmonary nodule include fluorodeoxyglucose positron-emission
tomography, technetium Tc 99m depreotide imaging, bronchoscopy with
bronchioloalveolar lavage and biopsy, image-guided transthoracic needle aspi-
ration biopsy, video-assisted thorascopic surgery, and thoracotomy.
Conclusions. The success of any radiological management of a solitary pulmo-
nary nodule rests on careful clinical evaluation and risk stratification for malig-
nancy before the implementation of appropriate imaging techniques.
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Introduction
This review article aims to provide a synopsis of current opinions on the radio-
logical management of a solitary pulmonary nodule (SPN). The findings from
this review could be used as a practical guide to both clinicians and radiologists
in their daily clinical practice. The changing roles of the ubiquitous chest radio-
graph, computed tomography (CT) techniques, and nuclear medicine imaging in
the pursuit of diagnosing or excluding a malignant SPN will be discussed.
An SPN is arbitrarily defined as a focal round or oval opacity with a diameter
of 3 cm or less, and which is completely surrounded by lung parenchyma.1 Nod-
ules larger than 3 cm have a substantially increased risk of malignancy and are
referred to as masses.2-4 In large-scale radiographic surveys, the incidence of
CME
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SPN ranged from 0.09% to 0.20%5-7 and the incidence of
malignant SPN ranged from 3% to 6%.3,5,8,9 Before the ad-
vent of CT, the incidence of malignant SPN as diagnosed
by histological examination of resected SPN was 30% to
40%.4,7-9 However, since the use of CT in the presurgical
diagnosis of benign SPN, the incidence of malignant SPN
has increased substantially, ranging from 60% to 80%.2,10
Lung cancer is the primary cause of malignant SPN,
followed by solitary metastasis, which is found in 10% to
30% of cases of resected SPN.3,4,9,11-13 Carcinoid and
primary lymphomas are other occasional causes of malig-
nant SPN.13 Despite improved surgical techniques and
the availability of new treatment regimens, the overall
5-year survival rate is 14% to 20%. The prognosis for
patients who have malignant SPN with an early clinical
tumour-node-metastasis (TNM) staging is significantly
better than for other patients. For example, clinical
stage 1A (T1N0M0) disease has a 5-year survival of 67% to
83%,14-16 compared with 20.2%, 5.1% and 7.9% for stage
IIIA, IIIB, and IV respectively.15 A malignant SPN with
a diameter of 3 cm or less thus represents potentially
curable disease in which the 5-year survival is inversely
related to nodule size at presentation.11,17
In clinical practice, most cases of SPN are benign. Healed
granulomas secondary to tuberculous or fungal infection
are the most common benign entities encountered, whereas
hamartomas, found in 10% of resected benign SPNs,
represent the next most common type of benign SPN.4,9,17,18
Hence, diagnostic investigations of SPNs aim at facilitating
the prompt and accurate identification of a benign lesion,
thereby avoiding unnecessary thoracotomies and allowing
prompt intervention if nodules are malignant.
Clinical evaluation
Before a physician starts characterising an SPN, several
clinical factors—such as age, smoking history, occup-
ational exposure (eg to asbestos), and previous malignant
disease—need to be addressed. Travel history to and from
areas where tuberculosis or fungal infections (eg coccidi-
oidomycosis and histoplasmosis) are endemic may be
important. In patients younger than 30 years, lung cancer is
rare unless there is a history of extrathoracic primary cancer,
in which case metastatic SPN is likely. In contrast patients
older than 40 years—particularly those with a history of
smoking—have a markedly increased likelihood of having
primary lung cancer.19
There is continuing debate over the clinical utility of
obtaining sputum for cytology in the routine investig-
ation of SPN.20,21 Nevertheless, in our practice at the Queen
Mary Hospital, sputum cytology is still performed as one
of the diagnostic tests of the SPN in persons in whom
lung cancer is suspected. The diagnostic rate for positive
sputum cytology in patients with malignant SPN is
low (<20%) and contributes mainly to the diagnosis of
squamous cell cancer because of its propensity for a
central intrabronchial site.20,22 False-negative sputum
cytology is prevalent (>60%) in patients with peripheral
lung cancers.21
Nodule detection
Computed tomography remains the most commonly used
and available radiological method to evaluate an SPN after
initial detection with a chest X-ray.20 A low-dose helical
screening scan (of 7- or 10-mm slice thickness, 50 mA)
can be performed in the first instance to locate the SPN
and to screen for other nodules.23 Retrospective reconstruc-
tion into thinner slice intervals or, with multislice scanners,
reconstruction into thinner sections could be performed.
The presence of other nodules in the lungs may suggest
metastatic disease or infection—the latter condition is
particularly indicated by the presence of satellite nodules.
Fig 1. (a) High-resolution computed tomogram showing a 3-cm spiculated solitary pulmonary nodule in the right-upper lobe
with pleural tags (arrows), later confirmed to be an adenocarcinoma; (b) Time-activity curve showing increase in
enhancement, reaching a plateau by 5 minutes
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Fig 2. Computed tomograms and high-resolution computed
tomograms showing different margin characteristics of solitary
pulmonary nodules
(a) Well-defined solitary pulmonary nodule with intranodular fat
densities noted as negative Hounsfield numbers on densitometry;
(b) lobulated nodule; (c) slightly spiculated and irregular nodule;
(d) polygonal nodule; and (e) a small nodule with surrounding
ground-glass opacification (halo sign)
(d)
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(a)
(b)
Fig 3. Computed tomograms showing a cavitating mycetoma
Note subpleural position of the solitary pulmonary nodule (arrow)
with coarse spiculations and cavitation on (a) lung and (b) medi-
astinal window settings, respectively
Although synchronous tumours may exist when two nod-
ules are found by CT, this situation is extremely rare.24 We
routinely perform contiguous high-resolution CT scans (at
1-3 mm) through the nodule to define morphology of an
SPN, followed by contrast-enhanced helical scans through
the nodule and rest of the thorax. Thin-section CT, particu-
larly with high resolution, is more accurate in detecting
calcification than is conventional CT. The detection of a
benign pattern of calcification can obviate further nodule
evaluation.2
Nodule characterisation
The determination of the nature of an SPN using a method
of imaging rests partly on its morphological features, such
as nodule size, margins, density, presence of fat or cal-
cification, and enhancement characteristics. A combina-
tion of certain features may suggest either a benign or ma-
lignant lesion. For example, a spiculated uncalcified 3-cm
nodule with enhancement (Fig 1) in a 65-year-old man with
a life-long history of smoking 20 packs of cigarettes per
day would very likely be malignant. Conversely, the 1-cm
non-enhancing nodule with smooth borders and intranodular
fat in a 20-year-old athlete would in all likelihood be
benign (Fig 2a). However, an overlap of features generally
occurs, rendering the task of estimating the likelihood of
malignancy in an SPN even more challenging.
Size
Whether one uses chest radiography or CT to evaluate
SPN, a general rule is that the larger the nodule is, the more
likely it is to be malignant; the smaller it is, the more likely
it is to be benign.2-4,13,25 Gurney26 analysed the likelihood
ratios for malignancy in four groups of SPN derived from
1080 patients: nodules that were 2 to 3 cm and larger
than 3 cm in diameter had substantially larger likelihood
ratios for malignancy (3.67 and 5.23, respectively) than
smaller SPNs of 1 to 2 cm and less than 1 cm in diameter
(0.74 and 0.52, respectively).2,25,26 That is, at least 80% of
SPNs larger than 2 cm that are identified by CT will be
malignant.2,13,25 However, with low-dose CT to screen for
lung cancer in high-risk populations, very small nodules
(<1 cm) are increasingly reported to be malignant.27-29 In
the Early Lung Cancer Action Project study, the annually
repeated CT screening of high-risk patients yielded 16 cases
with suspicious nodules, of which eight were proven
to be lung cancer; the mean size of these nodules was 8 mm
(range, 2-25 mm).27 Furthermore, lung cancer was found
in 38% of nodules of less than 1 cm that were removed
during video-assisted thorascopic surgery in 37 patients
without previous malignancy.29
Margin characteristics
The four categories of nodular margin that are commonly
described in clinical practice are (1) smooth and regular
(Fig 2a); (2) moderately smooth or slightly lobulated (Fig
2b); (3) slightly spiculated or irregular (Fig 2c); and (4)
grossly irregular with spiculations (Figs 1 and 3).25 Most
malignant SPNs have irregular and spiculated margins,
whereas benign nodules are generally well defined and have
smooth margins.2,25,26,30 However, malignant nodules may
in some cases exhibit smooth and regular contours, and
benign nodules may have spiculated irregular margins
(Fig 3). Zwirewich et al30 correlated high-resolution CT
findings with disease state by using specimens of SPN
obtained from 98 patients: although spiculation was observed
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in 90% of primary lung cancers, it was also present in four
of five tuberculous lesions and one of two inflammatory
lesions.30 The spiculations corresponded to a desmoplastic
reaction that resulted in the radiation of fibrotic strands into
the surrounding lung parenchyma. Pleural tags were
an extension of this desmoplastic reaction, and although
more commonly found in malignant nodules (Fig 1),
they were also found in inflammatory nodules (Fig 3).30
In the same study, lobulation of SPNs, which represents
uneven growth, was more predictive of malignancy than
spiculation: the likelihood ratio for malignancy of 2.07,
compared with 1.29 for a spiculated nodule.
Two other margin types have been described: polygo-
nal—defined as sharply demarcated angular margins con-
cave towards the centre of nodule (Fig 2d)—and nodule
surrounded by a ‘halo’ of opacification resembling ground
glass (Fig 2e).31 The polygonal appearance is associated with
benign SPN and is attributed to fibrosis, dense infiltration
of inflammatory cells, alveoli collapse, and organisation of
the interlobular septae.31 However, surrounding emphysema
and intranodule fibrosis in a malignant SPN can also result
in a polygonal appearance.31
The CT halo sign was previously regarded as character-
istic of invasive aspergillosis, but it is now acknowledged
to be associated with infections such as candidiasis,
cytomegalovirus, herpes pneumonia, and tuberculosis, as
well as with non-infectious conditions such as Kaposi’s
sarcoma, metastatic angiosarcoma, and lung cancer.30-33
The ground-glass opacification in malignant SPN is
attributed to lepidic growth along the alveolar walls at the
edge of the solid invasive component.30,33,34
Internal characteristics
The presence of calcification, fat, cavitation, and air-
bronchograms within an SPN are useful indicators of
whether the nodule is benign or malignant. At our institution,
Fig 4. Computed tomograms and X-rays of a solitary pulmonary nodule
(a) a well-defined solitary pulmonary nodule with uniform calcification on plain computed tomogram; (b) a solitary pulmonary nodule
with laminated calcification on chest X-ray; (c) a subpleural nodule with eccentric calcification on plain computed tomogram; and
(d) a solitary pulmonary nodule with air bronchograms (arrowheads) confirmed to be bronchioloalveolar cell carcinoma in the right-
upper lobe on contrast-enhanced computed tomogram
(b)
(a) (c)
(d)
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contiguous high-resolution thin CT sections (1-3 mm)
through the nodule is routinely performed to detect calcifi-
cation and characterise internal features, particularly in small
nodules (<1 cm); this approach eliminates partial-volume
effects, which are associated with the use of thicker
conventional CT (8-10 mm) sections.2,18,20,21 The pattern of
calcification within an SPN has been extensively studied
and reviewed.2,25,35,36 Computed tomography is more
sensitive and accurate than plain radiography in the detec-
tion and characterisation of calcification patterns.25,37
Uniform, central, laminated, and ‘popcorn’ calcification
(Figs 4a and b) are indicative of a benign nodule such as
granuloma or hamartoma,25,35,36,38 whereas SPNs with eccen-
tric (Fig 4c) or stippled (dystrophic) calcification are sug-
gestive of a more sinister pathology.1,30,39 Eccentric
calcification may be due to tumour engulfment of pre-
existing calcified granuloma, and stippled calcification may
be due to dystrophic calcification of tumour necrosis.
The presence of intranodular fat (Fig 2a) of -40 to -120
Hounsfield units (HU) is even more indicative of a benign
lesion such as hamartoma or lipoid pneumonia than is
calcification.39 Up to 50% of hamartomas will contain
intranodular fat, of which a quarter will be in the typical
popcorn pattern on a CT scan.38 Other internal features, such
as low-density ‘bubbly’ areas (pseudo-cavitation) and air-
bronchograms (Fig 4d), are suggestive of bronchioloalveolar
carcinoma and lymphoma.30,40,41 Even though a benign SPN
may display this sign, the prevalence (<6%) is much lower
compared with malignant SPN (up to 65%).40,41 Cavitations
can occur in both benign and malignant SPNs, although
malignant cavitating SPNs generally have thick and irregu-
lar walls.30,42 A wall thickness of 4 mm or less has been
reported to suggest benign pathology, whereas a wall thick-
ness of 16 mm or more is almost always associated with a
malignant nodule.42 A considerable overlap of benign and
malignant entities, however, exists for wall thicknesses
between 4 and 16 mm (Fig 3).
Densitometry
Densitometry was first used in 1980 to detect calcification
in SPNs, whereby the detection of pixel densities of greater
than 164 HU was indicative of a benign nodule.43 This tech-
nique was not entirely successful because of technical fac-
tors arising from differences in scanner specifications and
reconstruction algorithms, prompting the development of a
reference ‘phantom’ with a density of 185 HU, against which
measurement of a nodule could be compared.44,45 However,
calcification could clearly be seen in 50% of nodules on
thin-section CT without requiring the phantom.44 In addition,
improvements in scanner technology, such as use of helical
and multislice scanning, have obviated the need for a
phantom. At the Queen Mary Hospital, we perform densit-
ometry without a phantom and regard nodules with pixel
densities of more than 200 HU as indicative of the presence
of calcification (Fig 5). It must be emphasised that densit-
ometry has little place in the evaluation of a spiculated
SPN, which should be treated in all cases with a high
degree of suspicion for malignancy.
Nodule enhancement
The predictive value of nodule enhancement in the eva-
(a)
(b)
Fig 5. Low-dose computed tomograms of the thorax
(a) Lung (arrow) and (b) mediastinal windows of a 52-year-old man with atypical cells on sputum analysis show fibrosis in the left lung
apex with a small (<1 cm) nodule. Nodule density was measured to be 98.87 HU. On further interrogation with fine-section computed
tomography and densitometry, central calcified foci of >200 HU were noted, suggesting this was a granuloma
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luation of SPN has been confirmed by several studies.45-48
The use of a threshold value of enhancement of up to 15 HU,
as determined by subtracting the pre-enhancement
density from the peak enhancement density during the first
4 minutes of dynamic scanning, has yielded a sensitivity,
specificity, and accuracy of 98%, 58%, and 77%,
respectively, for predicting a benign SPN.48 This method,
however, is meticulous and involves dynamic scanning
through a nodule at 1, 2, 3, and 4 minutes after contrast
administration; furthermore, regions of interest are within
approximately 70% of the nodule’s short- and long-axis
diameters, as measured on mediastinal window settings.
Respiratory misregistration, cardiac motion artefacts,
and the lack of specificity are further limitations of
this technique. Inflammatory lesions and benign
nodules such as hamartomas also demonstrate signifi-
cant enhancement above the threshold range. Yamashita
et al46 and Zhang and Kono47 have attempted to clarify
these ambiguities by evaluating the enhancement patterns
of benign and malignant nodules using time activity curves
generated by dynamic scanning through the nodule. Gener-
ally, malignant SPNs tend to achieve gradual enhancement-
to-peak attenuation and eventually reach a plateau
(Fig 1b), whereas inflammatory SPNs show rapid enhance-
ment without a plateau, as well as an early decline of
attenuation.46,47 These results, however, have been difficult
to replicate.48
Rate of growth
The growth of an SPN is commonly measured in terms of
the doubling time (interval required for the SPN to double
in volume) and is an additional parameter that can be
applied to determine SPN activity and therefore risk of
malignancy. Because SPNs are typically spherical, the cal-
culation of the doubling time is based on that of the volume
of a sphere (4/3πr3), whereby an increase in diameter of
26% indicates a doubling of its volume. Malignant SPNs
grow exponentially with a variable range of doubling times,
ranging from 30 to 1077 days and from 52 to 1733 days
according to two studies.49,50 Benign nodules such as a
hamartoma or granuloma are usually stable and have dou-
bling times of more than 500 days.51,52 Inflammatory SPNs
can grow even faster than malignant nodules, with a dou-
bling time of less than 20 days.51 As a rule, doubling times
that are less than 1 month may indicate infection, infarction,
lymphoma, or fast-growing metastasis.52,53
Although the absence of detectable growth over 2 years
was previously used as an indicator of a benign nodule,
the predictive value for this criterion is only 65%.39,54
The scientific basis for this concept has been challenged
by several studies.49,50,55-57 It is now widely accepted that
lung cancers differ in their doubling times. In addition,
the rate of growth of lung cancers are also influenced by
both their morphology on CT scans and the histological
cell types. The doubling time is the longest for adeno-
carcinoma (mean doubling time, 116.0-223.1 days), and
next longest for squamous cell carcinoma (88.0-104.8 days),
large cell carcinoma (71.0-100.0 days), and small cell
(a)
(b)
Fig 6. Positron-emission tomography/computed tomography
scans
(a) Scan showing a single pulmonary nodule in the subpleural
portion of the posterior segment of the right lower lobe. The
nodule had a maximum specific uptake value of 3.8 without
uptake elsewhere, suggesting metastatic nodal or distant spread;
(b) Scan showing a false-positive scan in a solitary pulmonary
nodule in the right-upper lobe, with a maximum specific uptake
value of 4.2. Biopsy later proved it to be a tuberculoma
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carcinoma (30-80.9 days).49,55-57 In a study on small lung
tumours that were diagnosed during a large-scale lung
cancer CT screening programme, solid nodules on a
high-resolution CT scan had the shortest doubling time
(149 days), whereas tumours exhibiting focal ground-
glass opacities had the longest (813 days).50 Given these
findings, some investigators recommend serial follow-up
visits lasting more than 2 years, particularly if previous
imaging, be it CT scan or chest radiographs, was not
available.18,58 Tumour growth can be assessed with either
plain chest radiography or CT using standard two-
dimensional measurement. Current CT technology has
also made it possible for quantification of volumetric growth
rates in nodules.59
Image-guided biopsies
Image-guided transthoracic needle aspiration biopsies
(TNABs) are best reserved for SPNs that are peripherally
located, whereas bronchoscopic biopsies are most accurate
in sampling central and endobronchial lesions.23 Computed
tomography is invaluable in determining not only the site
and position of an SPN for biopsy, but also in determining
the most appropriate biopsy technique for the SPN. Fluor-
oscopy and CT remain the main imaging methods for
image-guided biopsy, although ultrasonography can be
used in peripheral SPNs, where the acoustic window is un-
limited by intervening lung parenchyma. The drawbacks of
CT-guided TNAB are the lack of real-time imaging and the
long time taken for image generation and reconstruction;
by comparison, fluoroscopic TNAB is inherently faster to
perform. The yield from TNAB can be as high as 95% in
a peripheral neoplastic nodule, and even higher in the
presence of an on-hand cytologist.23,60,61 Transthoracic
needle aspiration biopsies have a reported sensitivity
and specificity of 80% to 95% and 50% to 88%, res-
pectively.11,62 The method’s diagnostic yield increases with
nodule size, increasing from 60% in SPNs of 1 cm or smaller
to 80% in SPNs of 2 cm.58 False-negative TNAB results,
however, are found in 3% to 29% of cases, and a pneumo-
thorax complicates up to a third of TNABs.11,62,63
Nuclear medicine imaging
The role of nuclear medicine imaging, such as fluorode-
oxyglucose (FDG) positron-emission tomography (PET) and
technetium Tc 99m depreotide imaging, in the evaluation
of SPNs remain underutilised, partly because of availabil-
ity and cost restraints.64-67 A recent meta-analysis examin-
ing the diagnostic accuracy of FDG PET (Fig 6a) in
determining malignancy reported a mean sensitivity and
specificity of 96.8% and 77.8%, respectively, for any focal
lung lesion, and 93.9% and 85.8%, respectively, for pulmo-
nary nodules.67 The intermediate specificity of FDG PET
stems from false-positive results when imaging inflamma-
tory or infective tissue such as granulomas (Fig 6b), and
histoplasmosis, aspergillosis, and coccidioidomycosis
lesions. This problem is inherent in areas in which these
infections are endemic. Size limitations because of resolu-
tion constraints of the PET cameras have also resulted in
reduced sensitivities for nodules of less than 1 cm in size.65
In addition, bronchioloalveolar and carcinoid tumours may
give rise to false-negative results on account of their rela-
tively low metabolic rate. Despite these limitations, FDG
PET not only has a role in determining the likelihood of
malignancy in an SPN, but also helps in the staging of
malignant nodules. The method is particularly useful in
detecting occult metastasis, such as lymph node meta-
stasis.
Technetium Tc 99m depreotide is a synthetic cyclic
6–amino acid peptide analogue of somatostatin, which has
recently been approved in North America for use in the
evaluation of SPNs. Although somatostatin receptor expres-
sion in non–small-cell lung carcinomas (NSCLCs) has not
been demonstrated in vitro, NSCLC has been imaged using
somatostatin-analogue scintigraphy.64,66 The reported sen-
sitivity and specificity of technetium Tc 99m depreotide
imaging ranges from 93% to 96.6% and 73.1% to 88%,
respectively, which are comparable to those of FDG PET.
However, the mean size of SPNs that were imaged with this
technique ranged from 2.4 cm to 2.8 cm.64,66 Hence, the
issue of accuracy in detecting malignant SPNs of less than
1 cm remains unresolved.
Determining the likelihood of malignancy
The likelihood that an SPN is malignant can be determined
using likelihood ratios by the application of Bayesian
analysis.21,68 The predictors of malignancy that are common-
ly used to assess the likelihood of malignancy are based
mainly on the morphological appearance of the nodule; these
predictors include margin, size, and presence of calcifica-
tion and enhancement. Additional factors are patient’s age,
smoking history, and the stability of the nodule. Variables
that predict malignancy are an age of older than 60 years, a
nodule of larger than 1.5 cm diameter, history of smoking,
spiculated or irregular nodular margins, eccentric or stip-
pled calcification, a doubling time of 30 to 400 days, the
absence of satellite lesions, and an enhancement by more
than 20 HU.
Because patients’ demographic characteristics, culture,
and disease pattern, as well as the availability of imaging
modalities and radiological and clinical expertise, may vary
between institutions, it would be imprudent to suggest a
specific decision pathway in the radiological approach to
examining SPNs. Nevertheless, an attempt has to be made
to determine the stability of a nodule either retrospectively
using a previous chest X-ray or prospectively with serial
chest X-rays. An SPN that has been stable for at least 2
years according to a previous chest X-ray could be regarded
as currently stable, although further follow-up with 3-to-6
monthly serial chest radiography for another year is
advocated.51 At the Queen Mary Hospital, if after charac-
terisation with CT, an SPN has obvious malignant features,
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we routinely perform bronchoscopy with broncho-alveolar
lavage, and—depending on tumour site—we offer trans-
bronchial biopsy or TNAB. Video-assisted thorascopic
surgery of peripheral nodules and some central-lower lobe
lesions is also performed on selected patients who have no
contra-indications to surgery. This procedure carries mark-
edly reduced mortality and morbidity compared with open
thoracotomy for wedge resection,69,70 although the conver-
sion rate to open thoracotomy is approximately 20%.70
Other centres may advocate prompt thoracotomy in patients
with obvious malignant nodules who have no obvious
contra-indications to surgery.51,62
Finally, FDG PET is increasingly used to determine
malignancy of SPNs at our institution. Decision-analysis
models have been used to study the impact of FDG PET on
diagnosis of an SPN: FDG PET imaging alone was found
to be superior to either traditional Bayesian approach or
FDG PET plus Bayesian approach in accurately determin-
ing whether a nodule is malignant or benign.71 A similar
study evaluating cost-effectiveness also found CT-plus-PET
strategy to be superior to conventional approaches.67 The
combined CT-plus-PET strategy showed the best incre-
mental cost-effectiveness ratio when the pre-test likelihood
of a malignant SPN was between 12% and 69%, whereas a
‘wait and see’ approach was most suitable for SPNs with a
pretest likelihood of less than 12%.72 Estimated cost
savings of US$91 to US$2200 per patient would be gener-
ated using the CT-plus-PET strategy.72
Conclusions
The radiological approach to studying an SPN involves
initial clinical evaluation with particular emphasis on
assessment of possible risk factors for malignancy. Previ-
ous chest X-rays should be retrieved in an attempt to
retroactively assess the stability of the SPN. If the nodule
has been stable for the previous 2 years, serial chest
radiography is still advocated, by some, for another year.
In the absence of previous chest X-rays, the SPN should
be characterised in detail with CT, with and without
enhancement. If a confident diagnosis of a benign no-
dule (calcified, fat-containing, and without enhancement)
is made with CT, further follow-up is usually not necessary.
In an SPN with malignant features, a more aggressive
approach should be pursued depending on the set-up of
the institution and wishes of the patient. Strategies that
could be implemented in the determination of malignancy
include FDG-PET, technetium Tc 99m depreotide imaging,
bronchoscopy, TNAB, video-assisted thorascopic surgery,
and thoracotomy.
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